Details of issuance or disposal
Monthly exercise status of stock acquisition rights with an exercise price adjustment clause issued through third-party allotment
Series 66 Stock Acquisition Rights: 3,220,000 new shares; Series 58 Stock Acquisition Rights: 0 new shares
The lower thin line represents the existing number of shares to which these shares will be added.
Exercise ratio subject to exercise restrictions: 6.6% (3,220,000 shares delivered for all series combined / 48,855,455 listed shares outstanding as of the payment date for the issuance)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
| Item | Details |
|---|---|
| Type of issuance or disposal | Monthly exercise status of stock acquisition rights with an exercise price adjustment clause issued through third-party allotment |
| Number of shares to be issued or disposed of | Series 66 Stock Acquisition Rights: 3,220,000 new shares; Series 58 Stock Acquisition Rights: 0 new shares |
| Intended allottee | Series 66 Stock Acquisition Rights: EVO FUND; Series 58 Stock Acquisition Rights: CVI Investments, Inc. |
| Dilution Rate | Exercise ratio subject to exercise restrictions: 6.6% (3,220,000 shares delivered for all series combined / 48,855,455 listed shares outstanding as of the payment date for the issuance) |
| Total number of issued shares | 72,238,910 shares (as of the end of the month preceding the target month, including 91,169 treasury shares) → Not disclosed |
| Exercise price | Series 66 Stock Acquisition Rights: ¥92–¥114 per share during the target month. Series 58 Stock Acquisition Rights: ¥86 per share. Details of the adjustment clause and the floor price: Not disclosed |
| Number of Stock Acquisition Rights | Series 66 Stock Acquisition Rights: 200,000 issued in total, with 167,800 unexercised at the end of the target month. Series 58 Stock Acquisition Rights: 20,000 issued in total, with 20,000 unexercised at the end of the target month |
| Most recent equity financing | 1 June 2022: Issuance of Series 58 Stock Acquisition Rights (detailed amount: Not disclosed), 12 August 2025: Issuance of Series 65 through Series 67 Stock Acquisition Rights (detailed amount: Not disclosed) |
Items this document does not state (20)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Following the issuance of Series 65 through Series 67 Stock Acquisition Rights dated 12 August 2025, the Series 58 Stock Acquisition Rights came to be deemed “MSCBs, etc.” as defined by the Tokyo Stock Exchange, and their monthly exercise status is therefore disclosed. Under the purchase agreement, the Series 67 Stock Acquisition Rights were structured so that, in principle, they cannot be exercised until 13 August 2027, and disclosure of their monthly exercise status has therefore been omitted.